AROG4-01 / Aromics Therapeutics - LARVOL DELTA

First in human phase 1 dose escalation and expansion clinical trial to evaluate the safety, pharmacokinetics and antitumor activity of intravenous AROG4-01 in patients with advanced solid tumors. (ASCO 2025) - P1 | "Serum samples collected from patients enrolled in part A whenreceiving the first IMP dose during the first treatment cycle will be used to assess the PK of AROG4-01. Three sites in Spain are expected to participate."

Clinical • Metastases • P1 data • PK/PD data • Mesothelioma • Oncology • Solid Tumor

First in human phase 1 dose escalation and expansion clinical trial to evaluate the safety, pharmacokinetics and antitumor activity of intravenous AROG4-01 in patients with advanced solid tumors (AACR 2025) - P1 | "Three sites in Spain are expected to participate. Recruitment is not yet open."

Clinical • Metastases • P1 data • PK/PD data • Mesothelioma • Oncology • Solid Tumor